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Whole-genome sequencing (WGS) is being increasingly utilized for the diagnosis of 
neurological disease.  The advent of next-generation sequencing (NGS) has replaced Sanger 
sequencing due to its ability to sequence millions of fragments in parallel, in real-time. It’s 
application in targeted gene panels and whole-exome sequencing (WES) has revolutionized 
standard investigation practices of neurodevelopmental diseases (NDDs).  WGS utilizes NGS 
technology in order to sequence beyond the exome and into the remaining 98-99% of the genetic 
code comprising the genome. In addition to increased coverage, WGS allows for the detection of 
novel gene variants, copy number variants (CNVs) and single nucleotide variants (SNVs) that 
are not traditionally picked up by WES. Furthermore, RNA sequencing (RNA-Seq) of the blood 
used in conjunction with WGS may have the ability to validate WGS findings by analyzing gene 
expression in addition to identifying novel RNA species within the transcriptome. The objective 
of this retrospective study was to measure the diagnostic yield of trio-based WGS and RNA-Seq 
against that of negative or inconclusive WES in a patient cohort comprised of complex 
neurological phenotypes. Whole genome sequencing was performed by Medical Neurogenetics 
LLC, a CLIA-certified laboratory in Atlanta, Georgia. This laboratory utilized the Illumina 
NovaSeq 6000 Sequencing System, with a goal of 30x coverage of 99% of mapped genome 
regions. Alignment and variant interpretation was performed by Dragen v2.2 and CNV analysis 
by Dragen v2.5. Variants were assessed in accordance with current ACMG criteria. WGS with 
complementary RNA-Seq resulted in 7 solved patient cases, providing a 31.8% yield. This 
phenotypically complex cohort was comprised of a spectrum of neurological conditions with 
suspected underlying genetic mechanisms. The use of WGS in conjunction with RNA-Seq 
resulted in a markedly increased diagnostic yield over that of preceding WES and conventional 
 iii 
first-tier tests which included chromosomal microarray, targeted gene panels, and metabolic 
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Technological advances in genetic sequencing over the last decade have had considerable 
impact on genetic testing in both clinical and research settings.  Next generation sequencing 
(NGS) has consequently replaced Sanger sequencing when testing for phenotypically variable 
syndromes due to its ability to sequence large numbers of genes simultaneously at a reduced 
cost. This has led to NGS being applied to targeted enrichment methods in addition to whole-
exome sequencing (WES) and whole-genome sequencing (WGS) techniques (Petersen et al., 
2017). The high resolution of NGS technology utilized in modern-day gene sequencing has 
allowed for the accelerated discovery of neurodevelopmental disease (NDD) associated genes 
(Srivastava et al., 2019). 
There is a high level of complexity with respect to the evaluation of NDDs and the 
introduction of WGS to current first-tier standard diagnostic testing technologies. Current 
workup of NDDs in the clinical setting include chromosomal microarray analysis (CMA), 
karyotype, MRI and/or ultrasound imaging, Fragile X syndrome (FXS) testing, metabolic testing, 
and mitochondrial DNA (mtDNA) sequencing (Srivastava et al., 2019). In addition to these first-
tier tests, WES has also been applied in clinical settings due to its significantly higher diagnostic 
yield in comparison to that of CMA. 
A molecular diagnosis is important for patients living with NDDs and their families as it may 
impact clinical management (Srivastava et al., 2019). Introducing trio-based WGS subsequent to 
current first-tier tests with inconclusive WES, increases diagnostic yield due in part to its 
increased genomic coverage and ability to capture copy number variants (CNVs) and single 
nucleotide variants (SNVs). By applying a trio-based approach, novel variants can be ruled in or 
out during variant analysis and interpretation processes. 
 2 
Whole-Genome Sequencing vs. Whole-Exome Sequencing  
The exome encompasses approximately 95% of the protein-coding regions of the genome 
and comprises approximately 20, 000 genes, while accounting for just 1-2% of the genome itself 
(Alfares et al., 2018). It is thought that approximately 85% of the pathogenic variants responsible 
for Mendelian conditions occur in these protein-coding regions of the genetic code or within 
canonical splice sites (Majewski et al., 2011). Genetic variants associated with complex traits, 
such as those associated with NDDs, may occur outside of these protein-coding sequences. 
These genetic variations arise within the remainder of the genome and may affect regulatory 
elements required for gene expression such as promoter regions, enhancer regions, and silencer 
sequences (Dinger et al., 2018). Due to WGS’ ability to reach beyond the exome and capture the 
intronic regions not picked up by WES, it is currently considered the most comprehensive 
genetic test available (Gilissen at al., 2014).  
Moreover, it appears that WGS provides better coverage of exons and is less susceptible 
than WES to distortions and blind spots in addition to being better able to detect copy CNVs and 
complex genomic rearrangements, such as inversions (Mattick et al., 2018). In addition, WGS is 
less sensitive to GC content, increasing its likelihood of providing complete coverage within GC-
rich regions (Odgerel et al., 2019). WGS has facilitated the discovery of novel pathogenic 
variants in addition to the CNVs, genomic rearrangements, and SNVs that have been strongly 
associated with Mendelian conditions that are not picked up by traditional WES (Srivastava et 





The Benefit of RNA-Sequencing Analysis 
In addition to WGS, other multi-omic technologies such as epigenomics, lipidomics, 
metabolomics, and transcriptomics are sometimes being used as diagnostic tools for clinical 
cases. Evaluation of the transcriptome by RNA-Seq provides the benefit of analyzing the RNA 
by looking at alternative gene spliced transcripts, post transcriptional modifications, gene 
fusions, SNVs, changes in gene expression over time and differences in gene expression among 
different tissues.  When used in conjunction with WGS, assays which assess the impact of 
variants at the mRNA level, such as RNA-Seq, prove beneficial in evaluating the outcomes of 
variants within deep intronic regions, splice junctions, and untranslated regions (Richards et al., 
2015). Identifying genomic variation is important for establishing a relationship between 
genotype and phenotype and provides further insight into human disease (Piskol, Ramaswami, & 
Li., 2013). 
 
Whole-Genome Sequencing Limitations 
 Currently, a key limitation of WGS as a first-tier diagnostic test in the clinical setting is 
cost. The cost of the sequencing technology in addition to the cost of labour required during the 
interpretation process and the disclosure of results is a significant obstacle. WGS will likely 
become more widely used in the future as the cost decreases over time. Furthermore, ACMG 
guidelines are insufficient for the classification of deep intronic variants that can be detected by 
WGS (Richards et al., 2015). The current guidelines consist of a 5-tiered system of classification 







This retrospective study reports on the diagnostic yield of trio-based WGS with RNA-Seq 
in a cohort of patients who had initially been referred for evaluation of a complex neurological 
phenotype suspicious for an underlying genetic condition. All probands had negative or 
inconclusive WES results within the antecedent five years. The objective was to assess the 
diagnostic value of WGS and RNA-Seq after a negative or inconclusive WES result.  
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MATERIALS & METHODS 
Whole Genome Sequencing was performed by CLIA-certified laboratory Medical 
Neurogenetics, LLC in Atlanta, Georgia (CLIA ID# 11D0703390; George Lab Lic. Code 060-
381). Sequencing was performed by Illumina NovaSeq 6000 with a goal of 30x coverage of over 
99% of uniquely mappable regions of the genome.. Alignment and variant interpretation  (SNV 
and CNV) was performed by Dragen v2.6. Variants were assessed according to ACMG criteria 
(Richards et al., 2015). Sequencing of the mitochondrial genome was performed on an Illumina 
NovaSeq with a goal of >500-fold average coverage. Repeat expansions for ATN1, ATXN1, 
ATXN2, ATXN3, ATXN7, ATXN8, ATXN10, C9ORF72, TBP, and ZNF9 was assessed with 
ExpansionHunter version v2.5.5 and findings confirmed by repeat-primed polymerase chain 
reaction (Dolzhenko et al., 2017).    
In addition to WGS sequencing, RNA sequencing was also performed by Medical 
Neurogenetics. Next generation sequencing (NGS) libraries were created using the TruSeq 
Stranded Total RNA library (Illumina) kit. Sequencing was also performed on an Illumina 
NovaSeq 6000 instrument with a targeted sequencing yield of 22 giga base pairs (Gbp). RNA 
secondary analysis was performed following the Nature protocol, “Transcript-level expression 
analysis of RNA-seq experiments with HISAT, StringTie and Ballgown”. Additional RNA-seq 
analysis was performed using in-house developed analysis for differential expression and small 







The patient cohort consisted of 22 patients from 20 families who had initially been 
referred for evaluation of a complex neurological phenotype suspicious for an underlying genetic 
condition. The participants in this study were assessed in a pediatric and adult 
neuromuscular/neurogenetics clinic in Hamilton ON, Canada. The patient cohort was diverse 
with respect to ethnicity, age at first presentation, and age at which they underwent WGS 
(current median age: 20 y, current age range: 4 – 49 y). All cases had negative or indeterminate 
WES results within the antecedent five years. Detailed clinical summaries are available for each 
patient in the supplemental files.  
 
Solved vs. Unsolved Cases  
 For the purpose of this study we define a case as “solved” when the variant interpretation 
and analysis reveals a molecular explanation of the patient phenotype regardless of the WGS 
outcome. We have provided corresponding numbers from the Online Mendelian Inheritance in 




















In total, each of the 22 patients enrolled in the study had a complete clinical and final 
result available from WGS. Of these, 3 (13.6%) had positive WGS results, 16 (72.7%) had 
indeterminate results, and the 3 (13.6%) remaining patients had negative WGS results. When 
analyzed in conjunction with RNA-Seq results, we received a combined total of 7 (31.8%) 
solved patient cases (Table 1). WGS results are current as of 2019, reanalysis has not yet been 
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Notes: When analyzed in conjunction with RNA-Seq results, we received a combined total of 7 (31.8%) 
solved patient cases (Table 1).  WGS results are current as of 2019, reanalysis has not yet been performed. 


















Figure 1. WGS Results 
 
Notes:  Chart of WGS results showing the proportion of patient cases that yielded a negative, positive, 
or indeterminate result.   





In this study, WGS and RNA-Seq was performed for 22 patients with complex 
neurological phenotypes and previous negative or indeterminate WES results. The goal was to 
assess the diagnostic yield of WGS and RNA-Seq in patients with nondiagnostic WES results. 
Many studies have been conducted to report the diagnostic yield of WGS as a first-line test 
among a variety of conditions. In these study populations, the patients have either had no prior 
genetic testing or have undergone an array of genetic testing including targeted gene sequencing, 
sequencing panels, CMA, or WES. Our study differs as we are evaluating the diagnostic yield of 
WGS in a population who homogenously had inconclusive or negative WES completed prior to. 
At typical sequencing depth, WGS offers improved uniformity of exonic coverage 
compared to that employed by WES, in addition to increased coverage and longer read lengths. 
(Wilfert et al., 2017).  Demonstrated in Supplemental Case 9, WGS (trio) identified homozygous 
EXCOSC8 variants inherited maternally and paternally while WES (trio) in 2016 was negative. 
The lower coverage exhibited by WES in comparison to WGS in that region resulted in the 
variants being missed. The EXCOSC8 variants at c.98G>A (p.Arg33Lys) has been classified as 
likely pathogenic, accurately representing the patients unexplained phenotype rendering the case 
solved. 
WGS has the ability to sequence beyond the protein-coding regions of the genome and 
detect genomic variation outside of these regions, which play a role in the development of 
complex traits and diseases (Alfares et al., 2018).  WGS offers improved uniformity of exonic 
coverage compared to that employed by WES when restricted to regions covered by both 
platforms. For example, in gnomAD, 89.4% of the exome was covered by WES at 20x coverage 
while WGS covered 97.1% at this same threshold.  
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It is known that WGS allows for superior detection of copy number variations in known 
disease genes over both WES and CMA. This includes de novo mutation (DNM) identification in 
genes which were previously restricted to large CNVs. The identification of small deletions in 
known/candidate disease genes led to a diagnosis in Case 7 and sibling Cases 10a/10b. 
WES for siblings 10a and 10b (duo) was completed in 2015 and was negative.  WGS 
(quad) of the sibling pair in addition to each parent identified a homozygous deletion of exon 3 
within SLC44A1 in both siblings. This deletion was predicted to result in a frameshift at amino 
acid position 90 and the subsequent termination of 18 codons (Chapelle et al., 2019). SLC44A1 
encodes for choline transporter-like protein 1, which has recently been associated with a 
childhood-onset neurodegenerative condition with progressive ataxia, dysphagia, tremors, 
cognitive decline, dysarthria, and optic atrophy (Fagerberg et al., 2020).  
For Case 7, WGS was able to detect a deletion in exon 4 of ACBD5 which was not 
identified by CMA or WES. The patient, a 29-year-old female, was known to have one 
maternally inherited heterozygous variant of uncertain clinical significance in ACBD5 
(c.925G>T, p.Gly309Ter). At the time WES was performed in 2015 ACBD5 was listed as a 
candidate gene not yet associated with a human phenotype. WGS identified the maternally 
inherited ACBD5 variant in addition to the novel discovery of the exon 4 deletion, which was of 
paternal origin.  RNA-Seq detected the deletion in ACBD5 in approximately 48% of reads 
covering its position at c.935G>T (Table 1). 
Additionally, RNA-Seq was proved an added benefit to WGS in this cohort and provided 
a diagnosis for Case 20. WES for Case 20 was performed in 2017 and identified several variants 
of interest, including a homozygous splice site variant of uncertain significance in ACAD9 
(c.244+3A>G) and compound heterozygous variants (in trans) in candidate gene SLC25A10 
 14 
(c.G449A, p.R150H and c.C574T, p.P192S). The ACAD9 homozygous variants were not felt to 
be diagnostic at the time because there was not a match with the described phenotype. The 
classic phenotype of ACAD9-related mitochondrial complex I deficiency is muscle weakness, 
hypotonia, cardiomyopathy, liver failure, encephalopathy, and Reye-like episodes in 
infancy/childhood. The ACAD9 homozygous splice site variant was again identified by WGS 
and RNA-Seq in blood confirmed that exon splicing was affected by this variant. Ataxia is still a 
rarely reported phenotype of ACAD9-related mitochondrial complex I deficiency and it is likely 
that this patient represents a milder phenotype of this condition.   
In Cases 11 and 15, while unable to identify new variants or provide multi-omic support 
to the pathogenicity of variants, WGS and RNA-Seq led to a final diagnosis by acting as a 
reanalysis due to updated medical knowledge. Case 15 is a 9 year old male with congenital 
hypomyelination syndrome. WES in 2014 identified a heterozygous de novo variant of uncertain 
significance in SETX (c.23C>T, p.Thr8Met). Some heterozygous variants in SETX have been 
associated with juvenile ALS type 4 (OMIM: 602433) while some biallelic variants have been 
associated with ataxia-oculomotor apraxia type 2 (OMIM: 606002). The SETX (c.23C>T, 
p.Thr8Met) variant has since been reclassified as “likely pathogenic” as we have been made 
aware of a few other cases of children with the same de novo variant in SETX and identical 
phenotype. Further work is being done to better characterize and publish this possible expansion 
in phenotype. 
Case 11 was known to have a likely de novo, likely pathogenic variant in POLG which 
was felt to explain part of his phenotype. A recent publication by Castiglioni et al. in 2018 
describes an expansion of the POLG phenotype which matches most of Case 11’s clinical 
symptoms. WGS also identified biallelic variants of uncertain significance in ZNF469 potentially 
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associated with Brittle cornea syndrome 1 (OMIM: 229200) and a heterozygous variant in 
EPHA2 of unknown parental origin possibly associated with autosomal dominant cataracts type 
6, multiple types (OMIM: 116600). It is presently unclear if these variants are playing any role in 




 In summary, WGS is revolutionizing the ability to diagnose complex neurological 
phenotypes associated with NDDs in addition to acute monogenic disorders. With the ability of 
WGS to poll more of the exome and reach the remaining 98-99% of the genetic code, WGS has 
the ability to produce a higher diagnostic return. In our study, a 31.8% diagnostic yield is 
reported by WGS subsequent to inconclusive or negative WES offered homogenously to this 
patient cohort.  
Other studies have reported the diagnostic yield of WGS to be as high as 21-34% in 
individuals with broad spectrum disorders or congenital malformations and neurodevelopmental 
disorders. These results parallel the results of our study. For example, Lionel et al. reported the 
diagnostic yield of WGS to be as high as 41%, which was higher than that of WES by 
approximately 26% (Lionel et al., 2018). It is worth mentioning that studies to support this claim 
are few, and the patient population in this study did not homogenously undergo WES prior to 
WGS. This emphasizes the need for additional studies directly comparing the diagnostic yield of 
WGS when performed subsequent to indeterminate or negative WES among the same patient 
population. In contrast to ours, a study by Alfares et al. found that prior to reanalysis, WGS 
yielded a positive result in only 7% of their patient population  subsequent to previously negative 
WES results (Alfares et al., 2018). 
 In addition to being less susceptible to distortions, rearrangements, and blind spots, WGS 
is also less sensitive to GC-rich content. With its additional ability to detect CNVs and SNVs, 
WGS identifies novel variants that are not identified by conventional or WES. Ultimately, WGS 
provides the complete dataset of an individual’s genetic composition.  
 17 
 Current ACMG classification guidelines do not directly apply to variants identified 
within deep intronic regions. This may be a contributing factor to the many variants resulting in 
negative or indeterminate findings within our study. Providing additional sequencing of the RNA 
transcriptome is becoming increasingly beneficial in establishing the significance of an 
increasing amount of VUS results being yielded by WES and WGS. RNA sequencing has proven 
useful in the identification of functional consequences of VUS results by providing examination 
at the mRNA level.  It has improved our ability to understand unknown variants by establishing 
their effects within both regulatory regions and coding regions of the genome. It can be 
integrated with WGS in order to interpret exonic and intronic SNVs and structural variants to 
increase the diagnostic rate. To our knowledge, our study is one of few to integrate RNA-Seq of 
the blood transcriptome into WGS in hopes of establishing increased diagnostic yield of complex 
neurological phenotypes. 
While our study focused on the benefits of NGS and diagnostic yield of WGS compared 
to WES, there are some limitations worth noting. Phenotypes presented in our study consisted 
only of complex neurological phenotypes, therefore, the results of our study may not be directly 
applicable across specialties. There is a need for more research on the efficacy of WGS outside 
of the neurologic setting. 
 A limitation to both WGS and WES is that a disease-causing variant may occasionally be 
overlooked if it has not yet been identified as such. If a variant is not yet identified as causative 
of a specific disease phenotype or the variant in question is within a gene of unknown function a 
diagnosis may be missed. This addresses the need for increased variant reporting especially in 
the case of extremely rare and phenotypically complex neurological diseases. 
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In addition, our study employed a trio-based approach to facilitate comprehensive 
interpretation of results, however, we did not address additional factors that may have influenced 
the diagnostic yield of WGS. For example, it was not clearly stated for each patient the degree of 
clinical involvement of a genetics team prior to their involvement with the neuromuscular clinic. 
This includes unknown frequency of consults with a geneticist and whether or not they had 
routine follow-ups with the genetics specialty prior to their involvement with our clinic. As a 
result, this may have directly impacted the amount of time elapsed before further comprehensive 
examination, testing and perhaps a diagnosis. 
Analysis and discussion of secondary findings was beyond the scope of our study; 
however, participants were informed of the possibility of secondary findings as per ACMG. The 
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An 11-y-old girl first presented at 16 mo of age with global developmental delay, 
hypotonia, bilateral ptosis, joint hypermobility, feeding difficulties, and failure to thrive (FTT). 
She was born weighing 5 lbs 8 oz at 36 wk by C-section after an induced labour due to placental 
abruption. At 20 mo of age she was not able to sit up on her own but could sit independently if 
placed in that position.  She was 3 y old when she had her first febrile seizure and 5 y old when 
she had her first unprovoked generalized tonic-clonic seizure with loss of consciousness. At last 
examination, she has profound intellectual disability, continues to have seizures, and is 
nonverbal. 
Karyotype analysis, array based comparative genomic hybridization (aCGH), CDKL5, 
Angelman and Rett syndrome testing were negative. Lactate levels ranged from 1.1 to 2.3 
nmol/L (N: 0.5 – 2.2 nmol/L) and she had a normal CK. Muscle ultrastructure pathology showed 
a minimal amount of mitochondrial pleomorphism. Enzyme testing of skeletal muscle revealed a 
mild complex I + III deficiency. NGS of mtDNA from skeletal muscle was negative for deletions 
but revealed a homoplasmic variant in the MT-ND4 subunit (m.11240C>T; p.Leu161Phe).  This 
variant was also homoplasmic in her asymptomatic mother and was thus considered to likely be 
benign.  
WES (trio) performed in 2014 was negative. In 2019, the result of WGS (trio) was 
negative. RNA-Seq of the entire fibroblast transcriptome did not identify any significant changes 
in transcript levels or splicing patterns in genes believed to be related to the clinical presentation 




This 33-y-old woman was born by uncomplicated delivery at term. She weighed 6 lb. 6 
oz and her Apgar scores were within normal limits.  She met all developmental milestones and 
there were no concerns until around 10 y of age when it was noticed that she had reduced vision. 
By 16 y of age she had been diagnosed with progressive visual loss due to retinitis pigmentosa. 
She could no longer perceive light by 32 y of age. 
At 17 y of age she started to show symptoms of progressive ataxia, also affecting speech. 
She became pregnant at 23 y of age and gave birth to a male child. Her condition worsened after 
birth with the commencement of seizures and severe and sharp headaches. By 30 y of age it 
became clear that she had a progressive neurodegenerative disorder. She was displaying 
abnormal behaviors and significant emotional outbursts with possible hallucinations and 
decreasing cognition. Physical examination found progressive spasticity and ataxia. She passed 
away at 33 y of age.  
Initial investigations included a muscle biopsy which showed normal pathology and 
muscle mitochondrial enzyme activities for complex I + III, IV and citrate synthase did not show 
a significant deficiency. Multiple brain MRIs showed significant atrophy of the cerebellum and 
vermis. 
WES (trio) was performed in 2014 and was negative. WES re-analysis in 2016 was also 
negative. WGS (duo) in 2018 identified two variants of uncertain significance. The two 
heterozygous variants of uncertain significance were identified, one in each of the SHANK3 and 
RELN genes. The SHANK3 (c.2863G>A; p.Ala955Thr) was of unknown parental origin and was 
not identified in large databases. The RELN variant (c.230C>T; p.Thr77Ile) was inherited from a 
clinically unaffected mother. RNA-Seq of the entire blood transcriptome did not identify any 
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significant changes in transcript levels or splicing patterns in genes believed to be related to the 







This 16-y-old boy who presented at 22 mo of age with global developmental delay, 
macrocephaly (54 cm, >98th percentile), and periventricular white matter changes. He 
experienced a seizure-like episodes once to twice a month with lip smacking, cyanosis of the 
lips, and breath holding. These episodes were usually followed by vomiting. Evaluation by a 
geneticist suggested a clinical diagnosis of MOMO Syndrome (Macrosomia, Obesity, 
Macrocephaly, and Ocular Abnormalities – OMIM# 157980). He remains largely non-verbal.  
Initial workup included mtDNA sequencing of blood and muscle tissue, genetic testing 
for Prader-Willi syndrome, a genetic epilepsy panel, transferrin isoelectric focusing, microarray, 
and metabolic screen.   WES (trio) was performed in 2014 and was negative. WES re-analysis in 
2016 was also negative. WGS (trio) was negative. RNA-Seq of the entire blood transcriptome 
did not identify any significant changes in transcript levels or splicing patterns in genes believed 






This 11-y-old female had a neurodegenerative phenotype with epilepsy, global 
developmental delays, and spasticity. Her development proceeded normally until ten mo of age 
when a stagnation in development and a slightly broad-based gait with stiff legs was noted. 
Regressions in her speech and motor skills became apparent at one year of age. Brain biopsy at 
three y of age was suggestive of a necrotizing encephalopathy. Seizures began around four y of 
age with a frequency of approximately five to eight per night. At five y of age she experienced 
an additional regression of cognitive and motor skills. She became fully non-verbal and 
experienced difficulties using her communication board. Due to increasing spasticity in her 
lower limbs she required assistance with walking (braces and orthotics). By the age of seven y 
her seizures occurred in clusters with a maximum of 25 within a timespan of 20 min each night. 
Each cluster involved multiple episodes of posturing and stiffened leg or arm stretches followed 
by post-ictal agitation. At age nine y of age she began having episodes of tonic stiffening during 
the day. Brain MRI at three and a half years of age showed multifocal areas of acute ischemia in 
the frontal lobes (bilateral), basal ganglia, and right cerebral peduncle. MR spectroscopy showed 
a decrease of NAA in relation to creatine and a lactate peak. Serial MRIs over the next several 
years showed continued slow progression.  
Initial investigations included enzymatic testing of hexosaminidase, B-galactosidase, and 
arylsulfatase. Genetic testing for Rett and Angelman syndrome, microarray, mtDNA sequencing 
and mtDNA deletion/depletion analysis in muscle tissue, a leukodystrophy panel, and an 
epilepsy panel were negative. Transferrin isoelectric focusing and immunoperoxidase for 
parvoviruses were both negative. Muscle biopsy of the right vastus lateralis at three y of age 
showed unremarkable pathology. Mitochondrial work up on fibroblasts, including analysis for 
complex V deficiency and lactate to pyruvate ratio were negative.  
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 WES was done in 2014 and identified one paternally inherited heterozygous likely 
pathogenic variant in SDHA (c.1532T>C; p.Leu511Pro). Biallelic pathogenic variants in SDHA 
have been associated with autosomal recessive Leigh syndrome (OMIM: 600857). 
Deletion/duplication analysis of the SDHA gene was normal and no second variant was 
identified.  
WGS (trio) was completed and identified compound heterozygous variants of uncertain 
significance (in trans) in ENTPD5 (c.916G>A, p.Glu306Ly + c.1229C>T, p.Thr410Met). The 
ENTPD5 gene encodes for an ectonucleoside triphosphate diphosphohydrolase but is currently a 
candidate gene and does not have any definitive disease associations in humans. No gene or 
phenotype matches were made through GeneMatcher (Sobreira et al., 2015).  Transferrin 
isoelectric focusing was unremarkable. RNA-Seq of the entire blood transcriptome did not 
identify any significant changes in transcript levels or splicing patterns in genes believed to be 






A 25-y-old man was born at 42 week gestation with Apgar scores of 2 @ 1 min and 7 @ 
10 min and was diagnosed with cerebral palsy in and this diagnosis persisted for the first 17 y of 
his life. He was first seen at 18 y of age with a complex phenotype of retinitis pigmentosa, 
scoliosis, cerebellar atrophy/hypoplasia, bilateral sensorineural hearing loss (SNHL), progressive 
generalized weakness, non-progressive ataxia, and significant contractures. During his most 
recent evaluation he reported a decline in strength and overall function with progressive 
cognitive decline and muscle atrophy. 
Initial work-up included a normal; aCGH, skeletal muscle mtDNA sequencing, and 
genetic testing for; Friedreich ataxia, POLG,  FCMD, FKRP, POMgNT1, POMT1,and POMT2. 
His CK was elevated at 901 iU/L (N: < 225 iU/L).  Muscle biopsy of the right vastus lateralis 
revealed extensive skeletal muscle atrophy with degeneration/necrosis, increased adipose tissue, 
and nonspecific mitochondrial changes.  
In 2014, WES (trio) identified one paternally inherited variant of uncertain significance 
in MYO1A (c.1165G>A; p.Asp389Asn). Pathogenic variants in MYO1A can be associated with 
an autosomal dominant nonsyndromic hearing loss (DFNA48) (OMIM: 607841) and the 
proband’s father felt that he had some non-specific hearing loss, although this was not clinically 
tested. In 2018, reanalysis of the WES results revealed no new findings. WGS (trio) identified 
the same MYO1A VUS that was identified on WES, but no other findings. RNA-Seq of the entire 
blood transcriptome did not identify any significant changes in transcript levels or splicing 







Cases 6a and 6b 
 
Case 6a is the 20-year-old male dizygotic twin of case 6b. He initially presented at 18 mo 
of age with global developmental delay and a history of seizures. His first febrile seizure was 
described as tonic-clonic and lasting approximately 30 seconds. Developmentally, he was able to 
sit independently at 18 mo and walk with support. Neurological examination at 18 mo found lax 
ankle joints, brisk symmetric reflexes, and macrocephaly (head circumference = 50.5 cm, >97th 
percentile).  
By three y of age he was experiencing myoclonic, convulsive, and focal seizures with left 
sided stiffening and postictal shivering. He could crawl, walk with support, and feed himself 
with his fingers. He had six to eight words in his vocabulary.  At ~ 5 y of age he had a regression 
while the frequency of seizures increased. At 16 y of age he displayed choreoathetosis and 
quadriplegic cerebral palsy-like features along with profound intellectual disability. By 20 y old 
he was having four to five generalized seizures per month, with a maximum seizure-free period 
was one week.  
Case 6b is the 20-year-old male dizygotic twin of case 6a. He presented with the same 
phenotype of global developmental delay, hypotonia, and seizures occurring approximately 17 
times a day. His head circumference was below the 90th percentile (49 cm).  By 16 y he also had 
choreoathetotic movements. Both brothers are non-verbal, and neither is currently able to walk 
independently or feed themselves.  
Diagnostic tests and investigations for the brothers included normal Initial investigations 
included; cardiac echocardiography, EMG/NCS, brain MRI, and hearing exams.  Vitamin E, 
urine MPS and oligosaccharides, arylsulfatase, beta-hexosaminidase, beta-galactosidase, 
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biotinidase, phytanic acid, serum acylcarnitine, and transferrin isoelectric focusing were 
unremarkable.  
Skin and muscle biopsies for case did not show any significant abnormalities or evidence 
of storage disease. Muscle analysis for case 6b was suggestive of reduced mitochondrial 
abundance with a mild reduction in complex I + III enzyme activity. NGS analysis of 
mitochondrial DNA revealed no deletions; however, there were two homoplasmic variants of 
uncertain significance;  MT-ND1:m.4084G>A; p.Val260Ile) and MT-ND2:m.5095T>C; 
p.Ile290Thr) identified as homoplasmic in his twin brother and mother.  Negative single gene 
testing included; aCGH, POLG1, SCN1A, Fragile X, Smith-Magenis, and Angelman syndrome. 
WES (quad) in 2015 identified two likely clinically unrelated variants of uncertain significance 
in both probands; a maternally inherited heterozygous VUS was identified in IDH2 (c.439G>C; 
p.Val147Leu) and a paternally inherited heterozygous VUS was identified in MYH2 
(c.2963T>C; p.Met998Thr). WGS (quad) was completed and revealed the same variants that 
were identified by WES. RNA-Seq of the entire blood transcriptome did not identify any 
significant changes in transcript levels or splicing patterns in genes believed to be related to the 








This was a 29-y-old woman born full term after an uncomplicated pregnancy and 
delivery. At six wk of age she presented with nystagmus and suspected blindness. By three y of 
age she had an ataxic gait and progressive incoordination. At eight y of age she had a mildly 
abnormal EEG showing interhemispheric asymmetry with intermittent right sided slowing 
posteriorly and slow background for age. She was diagnosed with retinitis pigmentosa at 15 y of 
age and had severe weakness requiring a wheelchair almost full time.  Brain MRI at 22 y of age 
were suspicious for neurodegeneration with brain iron accumulation (NBIA)/fatty acid 
hydroxylase-associated neurodegeneration (FAHN).  
Single gene testing was negative for NPC1, SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, 
SCA17, CYP7B1, SPG11, SACS, SPG7, SPG15, PNPLA6, SPG20, SPG21, CCT5, and SPG44.  
Muscle biopsy of her right triceps revealed a non-specific type 2 atrophy.  mtDNA sequencing 
and deletion/depletion analysis from muscle was negative. EMG/NCV, ECHO, and ECG were 
unremarkable.  
In 2014, WES (trio) identified four maternally inherited variants. A single pathogenic 
heterozygous variant in USH2A (c.2276G>T; p.Cys759Phe), a likely pathogenic heterozygous 
variant in PANK2 (c.1052C>T; p.Ser351Leu), a heterozygous variant of uncertain clinical 
significance in WFS1 (c.2453G>A; p.Arg818His), and a heterozygous VUS in candidate gene 
ACBD5 (c.925G>T; p.Gly309Ter). Deletion/duplication analysis was negative for PANK2 and 
USH2A and no second variant was identified.  
WGS (trio) was diagnostic for a newly described peroxisomal disorder associated with 
the ACBD5 gene. The results identified the previously found maternally inherited ACBD5 variant 
as well as a paternally inherited heterozygous deletion of exon 4 of ABCD5. Recent case reports 
suggest that loss of function variants in ACBD5 impair peroxisomal very long chain fatty acid 
 34 
metabolism (β – oxidation). (Ferdinandusse et al., 2017,  Yagita et al., 2017). Individuals have 
been described with retinal dystrophy/rod-cone dystrophy, abnormal eye movements, 
developmental delays, spastic paraparesis, hypomyelination, and signal abnormalities in the 
brainstem and deep white matter. (Abu-Safieh et al., 2013 Ferdinandusse et al., 2017,  Yagita et 






This case is a 31-y-old female with mild intellectual disability, optic atrophy, spasticity, 
and dystonia. Visual deficiencies were first noted at three and a half y of age and omnidirectional 
nystagmus was noted at 10 y of age, shortly after she was in a motor vehicle accident. At 15 y of 
age she continued to have progressive visual deficiencies along with declines in motor function. 
She experienced decreased mobility with sore knees, lower back pain, an inability to run, and a 
tendency to fall. Neurological examination at 22 y of age confirmed optic atrophy, ataxia, 
peripheral neuropathy, generalized weakness, and lower limb spasticity. Multiple repeated urine 
organic acid analysis showed a reproducible increase in lactate and pyruvate and significant 
increase in 3-methylglutaconic acid.  
Investigations included a swallowing study which revealed moderate oropharyngeal 
dysphagia. Brain MRI revealed bilateral symmetric abnormal signals. Muscle pathology and 
mtDNA sequencing was unremarkable, but metabolic enzyme testing was revealed a mild 
reduction in complex I + III. Genetic testing was normal for OPA1, OPA3, ARSA (MLD) and 
GALC (Krabbe disease).  
WES (trio) was performed in 2015 and was negative. WGS (trio) was negative. RNA-Seq 
of the entire blood transcriptome did not identify any significant changes in transcript levels or 







This is a 30-y-old female who first presented at 18 mo of age with global developmental 
delays. Over the ensuing year she developed dysarthria and progressive ataxia. She began using a 
wheelchair full-time around 12 y of age due to the progressive ataxia and weakness in her lower 
limbs.  Coenzyme Q10 (CoQ10) concentration in muscle tissue was found to be low (11.09 ng/g 
fresh tissue, N: >15 ng/g fresh tissue) and she was started on supplementation of CoQ10. Brain 
MRI at 12 y of age was unremarkable at the time. EMG was suggestive of a pure motor 
neuropathy or neuronopathy, suspicious for a Spinal- Muscular Atrophy (SMA)-like condition. 
Genetic testing for SMN1, COQ2, PDSS1, PDSS2, CABC1, CACNA1A, SYNE1, and COQ9 was 
negative.  
In 2016, WES (trio) was not diagnostic but found one paternally inherited variant of 
uncertain clinical significance in PLEKHG5 (c.2695G>A; p.Gly899Ser). Pathogenic variants in 
PLEKHG5 are associated with autosomal recessive Charcot-Marie-Tooth (CMTRIC) (OMIM: 
615376) and distal spinal muscular atrophy type 4 (DSMA4) (OMIM: 611067). 
Deletion/duplication analysis of PLEKHG5 was negative; consequently, this was considered to 
not likely be pathogenic. 
WGS (trio) identified a homozygous VUS in EXOSC8 at c.98G>A; p.Arg33Lys. 
Pathogenic variants in EXOSC8 have been associated with autosomal recessive pontocerebellar 
hypoplasia, type 1C (OMIM: 616081). This variant was not identified through WES because of 
poor read coverage in this area. Based on the patient phenotype a diagnosis of autosomal 
recessive pontocerebellar hypoplasia, type 1C was established (OMIM: 616081 ). RNA-Seq of 
the entire blood transcriptome did not identify any significant changes in transcript levels or 
splicing patterns in genes believed to be related to the clinical presentation of this patient.  
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Cases 10a and 10b. 
The proband (Case 10a) is a 23-y-old woman with intellectual disability, progressive 
ataxia, vision loss, spasticity, dysarthria, and mild proximal weakness. She was born at term to 
distantly consanguineous parents of Syrian descent. Parents reported normal milestones until 
around five y of age. By eight y of age she had experienced a regression of her fine and gross 
motor skills, dysmetria, nystagmus with saccadic eye movements, scanning speech, dysarthria, 
and progressive spinocerebellar ataxia and decreased visual acuity. By her late teenage y she was 
experiencing progressive dysphagia, severe truncal titubation, worsening bowel and bladder 
incontinence, increased tremor, lower limb spasticity, and further declines in balance and 
cognition.  
Case 10b is the 18-year-old younger brother of Case 10a. He presented with an identical 
history of intellectual disability, progressive ataxia, vision loss, spasticity, dysarthria, and mild 
proximal weakness. His first symptoms appeared around eight y of age with generalized 
weakness.  By 10 y of age he was unable to run and a positive Gower’s sign on examination.  
Similar to his sister, he developed dysarthria, dysphagia, scanning speech, ataxia with truncal 
titubation, saccadic eye movements, brisk reflexes, upgoing toes, and dysmetria. He also had 
moderate cognitive impairment and nighttime enuresis.  At 18 y of age he was diagnosed with 
osteoporosis. 
Initial investigations included brain MRIs for both siblings. The MRI of case 10a 
revealed white matter changes. An MRI in Syria for case 10b showed signs of leukomalacia in 
the periventricular areas. Repeat MRI for case 10b at 18 y of age revealed white matter changes, 
mild atrophy and an elevation of choline levels and iron deposition in globus pallidi and bilateral 
thalami suggestive of a neurodegenerative disease such as neurodegeneration with brain iron 
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accumulation (NBIA).  Other investigations for the siblings, such as EEGs, ECHOs, EGCs, 
EMG/NCV, muscle biopsy, measurement of CoQ10 levels in skeletal muscle, mtDNA 
sequencing, and metabolic analysis were unremarkable. Genetic testing included; aCGH, 
karyotype, NPC1, NPC2, CABC1, Friedrich ataxia, SCA 1, 2 3, 6, 7, 8, and 17, and a hereditary 
spastic paraplegia panel.   
WES for both siblings (duo) was completed in 2015 and was negative.  WGS (quad) was 
completed and identified a homozygous deletion of exon 3 of SLC44A1 in both siblings 
(Chr8:108,066,751-108,095, 501x0 (GRCh37)). SLC44A1 encodes for choline transporter-like 
protein 1. This deletion was predicted to result in a frameshift at amino acid position 90 and 
subsequent termination of 18 codons thereafter. Through GeneMatcher (Sobreira et al., 2015) a 
number of other individuals with biallelic variants in SLC44A1 have been identified with a 
similar childhood-onset neurodegenerative condition with progressive ataxia, dysphagia, 
tremors, cognitive decline, dysarthria, and optic atrophy (Fagerberg et al., 2020) . This was 
supported by in vitro work investigating choline transporter defects (Taylor, 2019).  RNA-Seq of 
the entire blood transcriptome did not identify any significant changes in transcript levels or 






This case is a 16-year-old boy who was referred to the neuromuscular clinic with a complex 
neurological disorder characterized by severe distal axonal peripheral neuropathy, progressive 
dysphagia, global developmental delay, congenital cataracts, glaucoma, corneal dystrophy, 
nystagmus, and retinal detachment.  
Testing included mtDNA sequencing, electron transport chain enzyme analysis in skeletal 
muscle, mass spectrometry and lab quantification of guanidinoacetate and creatine, and 
sequencing of CTDP1. Sequencing of POLG in 2008 identified a variant of uncertain 
significance (c.2852A>C; p.Tyr951His). The variant was not maternally inherited, and no 
paternal sample was available for family studies.  
WES (duo) in 2014 identified several variants of uncertain significance, including the same 
POLG variant identified previously. In 2012 the same POLG variant had been reported in 
another patient with distal myopathy with cachexia (Pitceathly et al., 2012). The POLG variant 
was felt to explain part of the proband’s phenotype (e.g. long-standing progressive muscle 
wasting and weakness, cataracts, and borderline CK elevation), but was not felt to explain the 
entirety of his phenotype. For example, there was no evidence of a large fiber peripheral 
neuropathy or ocular findings in the other reported case . Family studies to investigate the other 
variants identified by WES were not informative. This included biallelic variants of uncertain 
significance in ZNF469 (c.8260C>T; p.His2754Tyr and c.1457G>A; p.Arg486His) (Brittle 
cornea syndrome 1, OMIM: 229200), and a maternally inherited variant in DNM2 (c.2228C>T; 
p.Pro743Leu) (Centronuclear myopathy 1, OMIM: 160150). 
Because the entirety of this patient’s phenotype was not felt to be explained by the POLG 
variant, additional genetic testing was pursued. WGS (duo) in 2018 again identified the same 
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likely pathogenic heterozygous variant in POLG (c.2852A>C; p.Tyr951Ser). A recent 
publication by Castiglioni et al. in 2018 describes an expansion of the POLG phenotype which 
matches most of Case 11’s clinical symptoms.  
In addition to the POLG variant, WGS also identified the biallelic variants of uncertain 
significance in ZNF469 discussed above as well as a heterozygous variant in EPHA2 of unknown 
parental origin (c.1457G>A; p.Arg486His). Pathogenic variants in EPHA2 have been associated 
with autosomal dominant cataracts type 6, multiple types (OMIM: 116600). It is presently 
unclear if the variants in ZNF469 or EPHA2 are playing any role in the complex eye phenotype 
of this patient. RNA-Seq of the entire blood transcriptome did not identify any significant 
changes in transcript levels or splicing patterns in genes believed to be related to the clinical 





The case is a four-year-old girl with global developmental delay, microcephaly, hypotonia, 
hypermobility, and focal epilepsy. She was born by C-section at 38 weeks due to breech 
positioning and oligohydramnios. Reduced fetal movements were reported during the pregnancy. 
She presented at 4 mo of age with failure to thrive and hypotonia. Her head circumference was 
39 cm, just below the second percentile and she had a tent-shaped mouth. She was unable to sit 
independently at 18 mo of age but could lie prone and push up via arm extension. She was 
admitted at 2 y 6 mo for generalized, tonic-clonic status epilepticus with multiple febrile seizures 
within a 24-hour period, this was her first recorded occurrence. She had the ability to walk with 
the assistance of a walker but could not crawl or walk independently, and her development 
plateaued at 3.5 y of age. She is non-verbal and her communication is limited to shaking her 
head for “no”.  
Initial investigations included an EEG which was mildly abnormal with some bursts of 4 Hz 
sharp waves suggestive of propensity for focal seizures in this area. Brain MRI revealed a small 
pituitary cystic structure (4.6 mm),  periventricular leukomalacia, prominence of supratentorial 
CSF space with moderate dilation of supratentorial ventricles and moderate cerebral volume loss 
in the parieto-occipital region.  Microarray, EMG/NCV, CK, and a congenital muscular 
dystrophy panel testing were negative. 
WES (trio) was done in 2017 and identified a paternally inherited heterozygous pathogenic 
variant in TSEN54 (c.919G>T; p.Ala307Ser). Deletion/duplication analysis of TSEN54 did not 
identify a second variant and her MRI was not consistent with pontocerebellar hypoplasia.  WGS 
(trio) identified the same TSEN54 variant, but no other findings felt to explain her phenotype. 
RNA-Seq of the entire blood transcriptome did not identify any significant changes in transcript 
 42 








This case is a 6-y-old female born to non-consanguineous parents. At birth, she weighed 
5 lbs with microcephaly (measurement not available). She presented with her first seizure at four 
mo of age and an EEG at eight mo of age showed modified hypsarrhythmia consistent with 
infantile spasms. At five y of age her epilepsy worsened, and she was diagnosed with probable 
Lennox-Gastaut syndrome. MRI studies at fifteen mo of age showed microcephaly (HC = 43 cm, 
<3rd percentile), marked cerebral atrophy, and high T2 signal in the basal ganglia and 
cerebellum. At four y of age she was diagnosed with cortical blindness. Developmental 
regression and reduced hearing was noted at five and a half y of age, resulting in the loss of 
previously gained abilities including gross and fine motor skills and overall social interaction. 
Examination found spasticity and brisk reflexes in all four limbs. Chromosome aCGH was 
negative.  
In 2014, WES (trio) identified a single heterozygous paternally inherited variant in 
RMND1 (c.713A>G; p.Arg238Ser). Pathogenic biallelic variants in RMND1 are associated with 
(Combined Oxidative Phosphorylation Deficiency 11 (COXPD11), OMIM: 614922). No second 
variant in RMND1 was identified. Also found were two compound heterozygous variants of 
uncertain clinical significance in candidate gene TKT (c.133G>A; p.Ala45Thr and c.976C>T; 
p.Arg326Cys). Her TKT enzyme activity was reported as 7.3 nmol/mg protein/minute (controls: 
12.1—17.8). This activity of TKT in fibroblasts is decreased to approximately 50% of normal, 
which was not felt to be sufficient to be disease causing. WGS (trio) identified the previously 
reported variants in RMND1 and TKT. No additional variants were identified. RNA-Seq of the 
entire blood transcriptome did not identify any significant changes in transcript levels or splicing 




This case 14 is a 17-y-old woman born to consanguineous parents with intellectual 
disability, myoclonus, dystonia, chorea, supranuclear vertical gaze palsy, and dystonia. The 
initial onset of her movement disorder was observed at four mo of age and involved her arms, 
legs, hands, and tongue. These movements did not involve her face and did not occur in her sleep 
but worsened when participating in tasks. Her developmental milestones were globally delayed, 
she began to walk at the age of three and demonstrated speech and language delays. Assessment 
at age 12 y revealed that she was at a 6-y intellectual level. Her head circumference at this time 
was 56.5 cm (>97th percentile). She exhibited a supranuclear gaze palsy, oculomotor apraxia, and 
facial myoclonus with dystonia. Her speech articulation was affected by her movement disorder 
and vocal cord nodules. Her chorea was slowly progressive, and she reported occasional 
episodes of dysphagia when she had increased myoclonus. Nystagmus was noted on physical 
examination with slow-moving saccades in the horizontal plane, and she showed an inability to 
look downward past the midline. Examination at 17 y of age revealed dystonia in the hands with 
rapidly alternating movement and dystonia in her legs and feet. She had significant balance 
problems with a slightly broad ataxic gait.  
Initial investigations included a brain MRI which showed subtle diffuse periventricular 
white matter high signals on T2 weighted images. Urine metabolic screen, urine organic acids, 
serum copper, ceruloplasmin, lactate, and plasma amino acids were unremarkable. Molecular 
genetic analysis of NPC1, NPC2, and microarray were negative.  
WES (trio) was negative. WGS (duo) in 2018 detected a homozygous variant of uncertain 
significance in SCN3A (c.2204A>G; p.Asn735Ser). Pathogenic variants in SCN3A have been 
associated with an autosomal dominant familial focal epilepsy with variable foci (FFEVF4), 
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(OMIM: 604364). Since neither the proband nor either of her parents had a history of epilepsy 
this variant was felt to not explain the patient’s phenotype. RNA-Seq of the entire transcriptome 
from fibroblasts did not identify any significant changes in transcript levels or splicing patterns 





This case is a 9-y-old boy born at 41.5-wk gestation after a pregnancy complicated by 
polyhydramnios and decreased fetal movements. He had bilateral talipes equinovarus requiring 
serial casting and tenotomy of the left foot. He was delayed in meeting motor milestones. At age 
two he was able to sit with no supports and crawl independently. He was able to pull to stand but 
unable to support his full weight when standing. By four y he was able to walk with a walker. He 
had reduced fine motor skills due to significant distal weakness in his hands. Feeding was an 
issue due to choking spells when consuming fluids without a straw and swallowing studies 
revealed thin fluid aspiration and limited penetration without trace aspiration. His speech was 
impacted by vocal weakness/hypophonia.   
Nerve conduction studies and EMG revealed median and ulnar velocities of 
approximately 10 m/s and a diagnosis of congenital hypomyelinating neuropathy was suspected.  
Sequencing of EGR2, PRX, ENFL, LITAF, GDAP1, FGD4, FIG4, MTMR2, SH3TC2, NDRG, 
PMP22,  and MPZ were negative. 
In 2014, WES (trio) identified two variants in genes possibly associated with his reported 
phenotype. A heterozygous de novo variant at c.23C>T; p.Thr8Met)in SETX and a heterozygous 
paternally inherited VUS at c.2176G>A; p.Val726Met in IGHMBP2. Heterozygous pathogenic 
variants in SETX have been associated with (juvenile ALS type 4 (OMIM: 602433) while 
biallelic pathogenic variants in SETX have been associated with ataxia-oculomotor apraxia type 2 
(OMIM: 606002). Clinically it was felt that his phenotype was earlier onset and more severe than 
the phenotype described in juvenile ALS Type 4. Biallelic pathogenic variants in IGHMBP2 are 
associated with spinal muscular atrophy with respiratory distress type 1 (SMARD1) (OMIM: 
604320); however, deletion/duplication analysis of IGHMBP2 was negative and no second 
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variant was identified. SETX has a 42% shared homology with IGHMBP2 which also raised the 
possibility of a synergistic interaction between the variants identified in these two genes. WGS 
(trio) was completed and revealed the same variants identified by WES. No additional variants of 
interest were identified. RNA-Seq of the entire blood transcriptome did not identify any 
significant changes in transcript levels or splicing patterns in genes believed to be related to the 
clinical presentation of this patient.  
Since these results have been returned, we have been made aware of a few other cases of 
children with the same de novo variant in SETX (c.23C>T; p.Thr8Met) and identical phenotype. 







This case 16 is a 10-y-old girl born at 37 wk gestation after a pregnancy complicated by 
oligohydramnios and reduced fetal movements. She presented at six mo of age due to delays in 
meeting her gross and fine motor milestones. She gained the ability to walk independently at two 
y of age but continues to use a walker due to difficulty with balance. Evaluation at seven y of age 
found truncal hypotonia, intention tremor, balance problems that appeared cerebellar in nature, 
and spasticity and weakness in the lower extremities. She had moderate intellectual disability 
with roughly 30 words in her vocabulary and would use just two words together at a time. She 
was not toilet trained. Bilateral hearing loss was also documented at this time. A brain MRI at 9 
y of age showed a complex septate pineal gland cyst and persistent diffuse cerebellar volume 
loss prominent in the vermis. 
Initial investigations included normal; lactate, ammonia, electrolytes, ALT, AST, CK, 
cholesterol, 7-dehydrocholesterol, homocysteine, alpha-fetoprotein, acylcarnitine profile, plasma 
amino acids, total and free carnitine, vitamin B12, transferrin isoelectric focusing, and uric acid 
levels. Muscle biopsy of the right quadriceps skeletal muscle showed a slight enlargement of 
mitochondria with no paracrystalline inclusions. Respiratory chain enzyme activities and 
fibroblast studies for pyruvate dehydrogenase complex deficiency and pyruvate carboxylase 
activity were unremarkable.  
A myopathy panel identified a heterozygous de novo variant of uncertain significance in the 
RMND1 gene (c.759dup; p.His254Thrfs*2). Pathogenic variants in this gene have been 
associated with autosomal recessive combined oxidative phosphorylation deficiency 
(COXPD11) (OMIM: 614922). No second variant was identified. mtDNA sequencing, a 
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hereditary spastic paraplegia (HSP) panel, karyotype, microarray, and SCA 1, 2, 3, 6, 7, 8, 17 
were all negative. 
 WES (trio) in 2016 was negative. WGS (trio) identified the same de novo RMND1 
variant seen previously as well as a paternally inherited heterozygous likely pathogenic variant in 
SLC12A6 (c.2230C>T;  p.Arg744Ter). Neither variant was felt to definitively explain the 
patient’s phenotype. RNA-Seq of the entire blood transcriptome did not identify any significant 
changes in transcript levels or splicing patterns in genes believed to be related to the clinical 






This case is a 12-y-old girl born at 39 wk gestation by caesarean section after a pregnancy 
was complicated by mild placenta abruption at 27 weeks. Nystagmus was observed at birth and 
she was diagnosed with laryngomalacia and gastroesophageal reflux disease (GERD) during the 
neonatal period. Her first unprovoked seizure occurred at three mo of age with upward rolling 
eyes, full body convulsions, and apnea. EEG showed bifrontal epileptiform charges. Brain MRI 
showed delayed myelination and enlarged ventricles with prominent bifrontal extra-axial CSF 
spaces with cerebellar atrophy and diffuse volume loss.  
She was able to sit independently at three y of age and gained the ability to walk with a 
walker by age six y. She has limited fine motor skills and is not able to grasp objects. She is 
primarily non-verbal with the exception of “yes” and “no”. aCGH, Rett syndrome, metabolic 
screen, and routine bloodwork were unremarkable. She has multiple dysmorphic features such as 
a small and smooth philtrum pectus carinatum, high arched palate, bilateral pes planus, 2-3 digit 
syndactyly, and bilateral arachnodactyly.  
WES (trio) was negative. WGS (trio) revealed two variants of uncertain significance; one 
heterozygous maternally inherited variant in RANBP2 (c.5579A>C; p.Lys1860Thr), and a 
heterozygous paternally inherited variant in CHRNA2 (c.859_862delinsC; 
p.Phe287_Tyr288delinsHis).  RNA-Seq of the entire blood transcriptome did not identify any 
significant changes in transcript levels or splicing patterns in genes believed to be related to the 






This case is a 17-y-old woman with features of both spinocerebellar ataxia (SCA) and 
hereditary spastic paraplegia (HSP). She was born at full-term to non-consanguineous parents 
after an uncomplicated pregnancy and delivery. She met normal developmental milestones until 
8 mo of age when her development stagnated. Developmental regression was noted at age 10 mo 
as she was losing her balance and no longer cruising around furniture. By 15 mo she could no 
longer crawl or stand and was non-verbal. Her head circumference was 48 cm (>95th percentile). 
Brain MRI at 15 y showed mild cerebellar atrophy and VEP was indicative of abnormal visual 
evoked responses with slowing. Examination found clonus in both feet, upgoing toes, and 
excessive drooling. She eventually re-gained the ability to cruise along furniture, developed a 
pincer grasp, could point to objects she was interested in, and use monosyllables. At 15 y of age 
her balance was notably better, and she no longer required any gait assisting devices and was 
independent for all activities of daily living (ADLs). 
 Initial investigations included an unremarkable EEG.  Lactate, carboxyltransferase, 
electrolytes, CBC, TSH, glucose, very long chain fatty acids, cholesterol, triglycerides, 
ceruloplasmin, urine organic acids, plasma amino acids, urine purine/pyrimidine profile, 
guanidinoacetate, and creatine/creatinine ration were negative.  
Muscle pathology on a biopsy of skeletal muscle from the right vastus lateralis was 
unremarkable. Mitochondrial respiratory chain enzyme analysis on skeletal muscle revealed a 
mild complex I+III deficiency.  mtDNA deletion analysis of skeletal muscle tissue and mtDNA 
sequencing on cultured fibroblasts were both negative. Genetic testing for Rett syndrome, 
GAMT deficiency, Friedreich ataxia, SCA 1, 2, 3, 6, 7, 8, 17, a panel of nuclear genes associated 
with mitochondrial disease (N = 406), and aCGH were unremarkable negative.  
 52 
WES in 2014 was negative. WGS (trio) identified a few variants of uncertain significance 
in genes with autosomal recessive inheritance. One was a paternally inherited heterozygous 
likely pathogenic variant in KIAA056 (c.922C>T; p.Gln308Thr). Pathogenic variants in this gene 
are associated with autosomal recessive Joubert syndrome 26 (OMIM: 616784). A maternally 
inherited heterozygous likely pathogenic splice site variant in PNPT1 (c.1441+2T>A).  
Pathogenic variants within this gene are associated with autosomal recessive combined oxidative 
phosphorylation deficiency-13 (COXPD13) (OMIM: 614932).  A third heterozygous likely 
pathogenic variant was seen in SLC39A8 (c.610G>; p.Gly204Cys) and was also of maternal 
origin. Pathogenic variants in this gene have been associated with autosomal recessive congenital 
disorder of glycosylation type IIn (OMIM: 616721). No second variant was identified in any of 
these three genes. RNA-Seq of the entire blood transcriptome did not identify any significant 
changes in transcript levels or splicing patterns in genes believed to be related to the clinical 





This case is a 49-y-old woman with a complex neurodegenerative disorder and 
neuropsychiatric features. Parents report normal development until she experienced a significant 
regression with her cognition, speech, and gait after undergoing corrective surgery for scoliosis 
at 13 y of age. She required full-time use of a wheelchair by 15 y of age and was dependent on 
her parents for all ADL’s. At age 43 y she began to experience visual hallucinations, anxiety, and 
behavioural problems such as increased violence.   
MRI was suggestive of mitochondrial cytopathy with diffuse cerebral and cerebellar 
atrophy, basal ganglia loss, and T2 hyperintensity in the transverse pontine fibers. Increased 
choline and decreased N-acetylaspartate (NAA) were observed in basal ganglia. Genetic testing 
of NPC1, NPC2, SCA 1, 2, 3, 6, 7, 8, 17,  and Friederichs ataxia were all negative. Acylcarnitine 
profile, plasma amino acids, serum lactate, urine metabolic screen, and urine organic acids were 
unremarkable.  
WES in 2014 revealed compound heterozygous variants in trans in VPS13A (c.5884C>T; 
p.Arg1962Cys and c.8676C>T, p.Ile289Ile). VPS13A has been associated with autosomal 
recessive choreoacanthocytosis (OMIM: 200150), however this diagnosis was felt to not fit her 
clinical picture due to an absence of acanthocytes in her blood. WGS (duo) was negative. RNA-
Seq of the entire blood transcriptome did not identify any significant changes in transcript levels 






This case 20 is a 38-y-old woman with spinocerebellar ataxia, optic atrophy, and 
intellectual disability. She exhibited ataxia early in childhood and did not walk independently 
until after 18 mo of age. Her ataxia was slowly progressive, and she continues to have difficulties 
with ambulation requiring a wheelchair for longer distances. At 24 y of age she was diagnosed 
with bilateral optic atrophy and visual evoked potentials were abnormal with no observable 
peripheral or central responses. Physical exam found limited downgaze, horizontal nystagmus, 
ptosis, oculomotor apraxia, significant intention tremor, mild scanning speech, and truncal 
titubation.  
Initial investigations included a brain MRI at 14 y which was normal but by 28 y of age 
her MRI showed a prominence of the cerebellar fovea, vermis and CSF spaces in the posterior 
fossa. Nerve conduction studies showed evidence of a predominantly axonal sensorimotor 
polyneuropathy. Biopsy of the right sural nerve revealed axonal neuropathy and demyelination.  
Biochemical testing of skeletal muscle revealed normal levels of CoQ10 with a reduction in the 
enzyme activity of complex I + III.   
Genetic testing included molecular analysis for Friedreich ataxia, SCA 1, 2, 3, 6, 7, 8, 17, 
POLG, TWNK, microarray, and mtDNA sequencing in skeletal muscle tissue. Testing of 
cerebrospinal fluid found normal glucose, protein, and lactate levels.  
 WES (singleton) was completed in 2017 and identified a number of variants of uncertain 
significance, including compound heterozygous variants (in trans) in candidate gene SLC25A10 
(c.G449A; p.R150H and c.C574T; p.P192S). SLC25A10 encodes for a mitochondrial protein 
carrier, however no association with human disease had been reported to date.  
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In 2018, WGS (trio) highlighted a homozygous likely pathogenic splice site variant in 
ACAD9 (c.244+3A>G). Review of WES data showed that this variant was identified but was not 
felt to be diagnostic because it was not felt that there was a strong phenotype match. However, 
RNA-Seq in blood confirmed that exon splicing was affected by this variant. Pathogenic variants 
in ACAD9 are associated with mitochondrial complex I deficiency type 20 (MC1DN20). The 
classic phenotype is muscle weakness, hypotonia, cardiomyopathy, liver failure, encephalopathy, 
and Reye-like episodes in infancy/childhood. Ataxia is still a rarely reported phenotype of 
ACAD9-related mitochondrial complex I deficiency and it’s likely this patient represents a milder 
phenotype of this condition.   
 
